{"organizations": [], "uuid": "36c1db2971ca0e81dd85304db14740b6d452f1b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pharma-mar-licenses-marine-derived/brief-pharma-mar-licenses-marine-derived-payloads-to-seattle-genetics-idUSFWN1Q405B", "country": "US", "domain_rank": 408, "title": "BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.99, "site_type": "news", "published": "2018-02-14T15:31:00.000+02:00", "replies_count": 0, "uuid": "36c1db2971ca0e81dd85304db14740b6d452f1b3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pharma-mar-licenses-marine-derived/brief-pharma-mar-licenses-marine-derived-payloads-to-seattle-genetics-idUSFWN1Q405B", "ord_in_thread": 0, "title": "BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics", "locations": [], "entities": {"persons": [], "locations": [{"name": "seattle gene", "sentiment": "none"}, {"name": "seattle", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "seattle genetics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - PHARMA MAR SA:\n* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES\n* SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS\n* IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED Source text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T15:31:00.000+02:00", "crawled": "2018-02-15T20:26:38.005+02:00", "highlightTitle": ""}